Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Page 1
Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012-2016 Experience.
Higgins M, Volkova N, Moy K, Marshall BC, Bilton D. Higgins M, et al. Among authors: marshall bc. Pulm Ther. 2020 Jun;6(1):141-149. doi: 10.1007/s41030-020-00115-8. Epub 2020 Apr 18. Pulm Ther. 2020. PMID: 32304091 Free PMC article.
INTRODUCTION: In this long-term, postapproval, observational study, data from the US Cystic Fibrosis Foundation Patient Registry and the UK Cystic Fibrosis Registry were used to evaluate the impact of ivacaftor treatment on cystic fibrosis (CF) by comparing outcomes in iva …
INTRODUCTION: In this long-term, postapproval, observational study, data from the US Cystic Fibrosis Foundation Patient Registry and …
Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.
Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, Higgins M, Konstan MW, Sawicki GS, Elbert A, Charman SC, Marshall BC, Bilton D. Volkova N, et al. Among authors: marshall bc. J Cyst Fibros. 2020 Jan;19(1):68-79. doi: 10.1016/j.jcf.2019.05.015. Epub 2019 Jun 10. J Cyst Fibros. 2020. PMID: 31196670 Free article.
BACKGROUND: Ivacaftor is the first in a class of drugs, CFTR modulators, that target the underlying defect in cystic fibrosis (CF). This long-term observational safety study evaluated CF disease progression in patients treated with ivacaftor in a real-world setting for up …
BACKGROUND: Ivacaftor is the first in a class of drugs, CFTR modulators, that target the underlying defect in cystic fibrosis (CF). This lon …
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.
Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C, Konstan MW, Sawicki GS, Sewall A, Nyangoma S, Elbert A, Marshall BC, Bilton D. Bessonova L, et al. Among authors: marshall bc. Thorax. 2018 Aug;73(8):731-740. doi: 10.1136/thoraxjnl-2017-210394. Epub 2018 May 10. Thorax. 2018. PMID: 29748252 Free PMC article.
As ivacaftor is intended for chronic, lifelong use, understanding long-term effects is important for patients and healthcare providers. ...
As ivacaftor is intended for chronic, lifelong use, understanding long-term effects is important for patients and healthcare provider …
Cancer risk among lung transplant recipients with cystic fibrosis.
Fink AK, Yanik EL, Marshall BC, Wilschanski M, Lynch CF, Austin AA, Copeland G, Safaeian M, Engels EA. Fink AK, et al. Among authors: marshall bc. J Cyst Fibros. 2017 Jan;16(1):91-97. doi: 10.1016/j.jcf.2016.07.011. Epub 2016 Aug 15. J Cyst Fibros. 2017. PMID: 27539828 Free PMC article.
Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening.
Ren CL, Fink AK, Petren K, Borowitz DS, McColley SA, Sanders DB, Rosenfeld M, Marshall BC. Ren CL, et al. Among authors: marshall bc. Pediatrics. 2015 Jun;135(6):e1386-92. doi: 10.1542/peds.2014-3698. Epub 2015 May 11. Pediatrics. 2015. PMID: 25963008
The goal of this study was to determine the prevalence, clinical features, and short-term outcomes of infants with CRMS. METHODS: We analyzed data from the US CF Foundation Patient Registry (CFFPR) from 2010 to 2012. ...
The goal of this study was to determine the prevalence, clinical features, and short-term outcomes of infants with CRMS. METHODS: We …
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA. Heltshe SL, et al. Among authors: marshall bc. Thorax. 2016 Mar;71(3):223-9. doi: 10.1136/thoraxjnl-2014-206750. Epub 2015 Apr 24. Thorax. 2016. PMID: 25911223 Free PMC article.
To design trials evaluating PEx treatment factors, we characterise the heterogeneity of PEx care in adults and paediatrics, and correlate it with measures of clinical response including short-term and long-term lung function changes, change in symptom severity score …
To design trials evaluating PEx treatment factors, we characterise the heterogeneity of PEx care in adults and paediatrics, and correlate it …
A preliminary evaluation of the effectiveness of the Cystic Fibrosis Foundation Mentoring Program for Respiratory Care.
Richards KM, Lester MK, Chin MJ, Marshall BC. Richards KM, et al. Among authors: marshall bc. Respir Care. 2013 May;58(5):764-9. doi: 10.4187/respcare.01745. Respir Care. 2013. PMID: 23106825 Free article.
BACKGROUND: In 2008 the Cystic Fibrosis (CF) Foundation launched the Respiratory Therapy Mentoring Program, which pairs a respiratory therapist (RT) relatively new to CF (apprentice) with a highly experienced RT (mentor) from a similar CF care center. We wished to determine if we …
BACKGROUND: In 2008 the Cystic Fibrosis (CF) Foundation launched the Respiratory Therapy Mentoring Program, which pairs a respiratory therap …
Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.
Cystic Fibrosis Foundation; Borowitz D, Parad RB, Sharp JK, Sabadosa KA, Robinson KA, Rock MJ, Farrell PM, Sontag MK, Rosenfeld M, Davis SD, Marshall BC, Accurso FJ. Cystic Fibrosis Foundation, et al. Among authors: marshall bc. J Pediatr. 2009 Dec;155(6 Suppl):S106-16. doi: 10.1016/j.jpeds.2009.09.003. J Pediatr. 2009. PMID: 19914443 Free PMC article.
Mutations in the CFTR gene can cause CF, but not all CFTR mutations are disease-causing. The term CFTR-related metabolic syndrome (CRMS) is proposed to describe infants identified by hypertrypsinogenemia on NBS who have sweat chloride values <60 mmol/L and up to 2 CFTR …
Mutations in the CFTR gene can cause CF, but not all CFTR mutations are disease-causing. The term CFTR-related metabolic syndrome (CR …
Cystic fibrosis pulmonary guidelines: airway clearance therapies.
Flume PA, Robinson KA, O'Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, White TB, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee. Flume PA, et al. Among authors: marshall bc. Respir Care. 2009 Apr;54(4):522-37. Respir Care. 2009. PMID: 19327189 Free article.
The committee determined that, although there is a paucity of controlled trials that assess the long-term effects of ACTs, the evidence quality overall for their use in CF is fair and the benefit is moderate. ...
The committee determined that, although there is a paucity of controlled trials that assess the long-term effects of ACTs, the eviden …
Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Merlo CA, et al. Among authors: marshall bc. Chest. 2007 Aug;132(2):562-8. doi: 10.1378/chest.06-2888. Epub 2007 Jul 23. Chest. 2007. PMID: 17646236
Independent risk factors for MARPA included CF-related diabetes mellitus (hazard ratio [HR], 1.64; 95% confidence interval [CI], 1.11 to 2.43), long-term inhaled tobramycin usage (HR, 2.08; 95% CI, 1.56 to 2.77), and care at a CF center with a baseline MARPA prevalence in …
Independent risk factors for MARPA included CF-related diabetes mellitus (hazard ratio [HR], 1.64; 95% confidence interval [CI], 1.11 to 2.4 …
11 results